https://charts.traderzeitung.de/phases/US2312693094 string(1388) "{"isin":"US2312693094","name":"Curis Inc","stock_id_xnas":65845076,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.971,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.995,"close_at":"2026-09-22 21:16:00","complete":true,"perf_pct":2.4717},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.952,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-4.3216},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Curis Aktie News & Nachrichten

[WKN: A3ETJD | Symbol: CRIS]

Realtimekurs

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Curis gefunden werden.

Curis Nachrichtenticker öffnen

MT Newswires 13.08.2026 15:29 Uhr

Curis bewertet öffentliches Angebot im Wert von 5,6 Millionen US-Dollar mit auf das Gesundheitswesen ausgerichteten institutionellen Investoren

09:28 AM EDT, 08/13/2026 (MT Newswires) -- Curis (CRIS) teilte am Donnerstag mit, dass das Unternehmen ein öffentliches Angebot platziert hat, mit dem

MT Newswires 06.07.2026 16:12 Uhr

Curis nimmt 6 Patienten in Phase-2-Studie von Emavusertib bei chronischer lymphatischer Leukämie auf

10:11 AM EDT, 07/06/2026 (MT Newswires) -- Curis (CRIS) teilte am Montag mit, dass es die ersten sechs Patienten in eine Phase-2-Studie von Emavuserti